Transplant Complications Drug Development Pipeline Review 2018: Therapeutics Development, Assessment, Companies, Dormant & Discontinued Projects and Product Development Milestones - ResearchAndMarkets.com | Financial Buzz

Transplant Complications Drug Development Pipeline Review 2018: Therapeutics Development, Assessment, Companies, Dormant & Discontinued Projects and Product Development Milestones – ResearchAndMarkets.com

The “Transplant
Complications Drug Development Pipeline Review, 2018” report
has been added to ResearchAndMarkets.com’s offering.

Transplant Complications Drug Development Pipeline Review, 2018,
provides an overview of the pipeline landscape for transplant
complications. It provides comprehensive information on the therapeutics
under development and key players involved in therapeutic development
for graft-versus-host disease (GVHD), liver transplant rejection, kidney
transplant rejection and lung transplant rejection and features dormant
and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow
transplant and involves the newly transplanted donor cells attacking the
transplant recipient’s body. Symptoms include abdominal pain or cramps,
nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness
of breath, vaginal dryness and weight loss. Treatment consists of
immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a
healthy one. Following a transplant, the immune system may consider the
transplanted tissue as foreign and work against it. Patients can develop
complications and ultimately reject the new organ. Therefore,
immunosuppressive drugs are administered simultaneously.

These immunosuppressive drugs prevent the body from either identifying
or attacking the foreign organ via various immune responses, blocking
organ rejection and facilitating a successful transplant. There are 18
products in development for liver transplant rejection, 49 products in
development for kidney transplant rejection and 12 products in
development for lung transplant rejection.

Molecular targets acted on by products in development for
transplantation complications include tyrosine kinases, caspases and
chemokine receptors. Companies operating in this pipeline space include
Medeor Therapeutics, Amgen and Novartis.

Key Topics Covered:

1 Introduction

2 Therapeutics Development

3 Therapeutics Assessment

4 Companies Involved in Therapeutics Development

5 Dormant Projects

6 Discontinued Products

7 Product Development Milestones

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4nrkv4/transplant?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005493/en/

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!